Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Recursion Pharmaceuticals Inc RXRX

Healthcare Biotechnology
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative... see more

Recent & Breaking News (NDAQ:RXRX)

Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results

PR Newswire November 8, 2022

Recursion to Participate in Upcoming Investor Conferences

PR Newswire November 2, 2022

Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB

PR Newswire October 25, 2022

Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022

PR Newswire September 13, 2022

Recursion to Participate in Upcoming Investor Conferences

PR Newswire September 1, 2022

Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum

PR Newswire August 18, 2022

Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results

PR Newswire August 9, 2022

Recursion to Participate in Upcoming Investor Conference

PR Newswire August 2, 2022

Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

PR Newswire July 21, 2022

Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference

PR Newswire June 20, 2022

Recursion to Participate in Upcoming Investor Conferences

PR Newswire June 2, 2022

Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results

PR Newswire May 10, 2022

Recursion to Participate in Upcoming Investor Conference

PR Newswire May 2, 2022

Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

PR Newswire April 11, 2022

Recursion to Participate in Upcoming Investor Conferences

PR Newswire March 31, 2022

Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital

PR Newswire March 30, 2022

Recursion Publishes First Environmental, Social and Governance (ESG) Report

PR Newswire March 24, 2022

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results

PR Newswire March 23, 2022

Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation

PR Newswire March 18, 2022

Recursion Provides Updated Guidance on Clinical Trial Starts

PR Newswire March 3, 2022